DIRS.INFO The most relevant business & tech news

The Woonsocket, Rhode Island-based company also trimmed its full-year adjusted earnings forecast, citing the possibility of higher medical costs. For the three months ended Dec. 31, CVS Health earned $2.05 billion, or $1.58 per share. CVS Health officials said in November that investors should ground their expectations for 2024 adjusted earnings at the low end of a range of $8.50 to $8.70 per share. CVS Health now foresees 2024 adjusted earnings of at least $8.30 per share. Pharmacists and technicians — mostly for Walgreens and other big retailers like CVS Health — were involved.

Persons: That’s, — Organizations: CVS, CVS Health, Zacks Investment Research, Revenue, CVS Health Corp, Company, Medicare, FactSet, Pharmacists, Walgreens, Rite Aid Locations: Woonsocket , Rhode Island

Two major factors are behind the decline in the budget deficit this year, each of them one-off events that reflect the challenge for lawmakers in trying to close the growing gap between tax revenues and spending. Second, tax revenues are expected to increase because of better returns on financial investments and the collection of taxes from last year that the government postponed because of natural disasters. Over the next decade, the cumulative budget deficits will be 7% smaller than the nonpartisan CBO forecast last year. For instance, this time last year, the office projected the unemployment rate would jump to 4.7% in 2023, while the current unemployment rate is 3.7%. The CBO anticipates that the unemployment rate will hit 4.4% at the end of 2024.

Persons: Joe Biden, Joe Biden’s, Donald Trump’s, Trump, Jerome Powell Organizations: WASHINGTON, Congressional, Congressional Republicans, Social Security, CBO, Republicans

And yet, an antiviral treatment proven to lessen the chances of severe outcomes is going underused. The drug, Paxlovid, is lauded by experts as a powerful tool that can prevent hospitalization and death from COVID-19. One Centers for Disease Control and Prevention study found that Paxlovid can decrease hospitalization risks among adults by 51%. The study by Harvard researchers found that Paxlovid was disproportionately given to Medicare patients with lower risk of severe infection. “There are very few medications and very few patients whose potential medication interaction with Paxlovid is so severe that they’re better off not taking Paxlovid,” he said.

Persons: they’ve, ”, Amesh, Paxlovid, Kurt Proctor, Celise Ballow, Ballow, “ I’m, I’m, … I’m, ” Ballow, ’ ”, Sarah George, Michael Barnett, Robert Wood Johnson Organizations: Johns Hopkins University, Disease Control, Pfizer, National Community Pharmacists Association, St, Louis University, Harvard, Associated Press Health, Science Department, Robert Wood Johnson Foundation, AP Locations: COVID, U.S, Junction , Utah, Paxlovid, Harvard

☆ Medicare now negotiating price of drug that costs $7,100 in US vs. $900 in Canada
▼ + stars: | 2024-02-06 | by ( Tami Luhby | ) edition.cnn.com time to read: +3 min

The annual list price of Bristol Myers Squibb’s Eliquis, a blood thinner that reduces the risk of stroke, is $7,100 in the US. Johnson & Johnson’s arthritis drug Stelara carries an annual list price of $79,000 in the US. Johnson & Johnson declined to comment on Sanders’ report. Medicare launches drug price negotiationsOther nations typically pay far less for medications, in large part because their governments often determine the cost. Those who have yet to meet their deductible and the uninsured may have to pay the full list price.

Persons: CNN — Sen, Bernie Sanders, Bristol Myers, it’s, Johnson, Sanders, drugmakers, Biden, Donald Trump, Sanders ’, Bristol Myers Squibb, Merck Organizations: CNN, Bristol, Health, Education, Labor, Pensions, Johnson, Merck, Bristol Myers Squibb, Medicare, Bristol Myers Locations: Japan, Canada, Germany, United Kingdom, France, Vermont

☆ The red-hot health-plan business for seniors is finally cooling off
▼ + stars: | 2024-02-06 | by ( ) www.businessinsider.com time to read: +6 min

Read previewHealth insurance giant Cigna is exiting the lucrative senior business that's been a boon to insurers' bottom lines for years. It's a sign that the glory days of Medicare Advantage might be coming to an end. Cigna's senior business isn't the biggest, but it's also nothing to sneeze at. In January, Humana, the second-largest Medicare Advantage insurer with 6 million members, slashed its profit projections because of these costs. AdvertisementIn late 2023, rumors swirled that Cigna was looking to sell its Medicare Advantage plans so it could pull off a merger with Humana—the second-largest Medicare Advantage insurer.

Persons: —, that's, Cigna, it's, It's, David Cordani, Cordani, Gary Taylor, Cowen, Taylor, Dean Ungar, Humana, Ungar Organizations: Service, Health Care Service Corp, Medicare, Business, Kaiser Family Foundation, Competition, Humana, Moody's Investors Service Locations: Illinois

Elsewhere, Goldman Sachs reiterated a buy rating on Nvidia and raised its price target on the high-flying semiconductor maker. Yet his price target sits at $225, implying an upside of 19.7% as he sees opportunity elsewhere. "Anyone pulling up a chart of UBER share price performance in 2023 will think, 'That's a scary chart. Analyst Sarah James upgraded the insurer to overweight from neutral and hiked her price target o $372 from $334. — Alex Harring 5:42 a.m.: Goldman hikes Nvidia price target Things continue to look up for Nvidia , according to Goldman Sachs.

Persons: Goldman Sachs, Piper Sandler, Alexander Potter, Potter, Tesla, Alex Harring, Bernstein, Uber, Nikhil Devnani, Devnani, — Alex Harring, Keith Horowitz, Horowitz, Cantor Fitzgerald Cigna, Cantor Fitzgerald, Sarah James, James, Ben Hendrix, Hendrix, Christopher Horvers, Horvers, Barbie, Goldman, FY4Q, Toshiya Hari, Fred Imbert Organizations: CNBC, JPMorgan, Mattel, Nvidia, Citi, Investors, Citizens, Financial, New York Community Bancorp, Aozora, T Bank, RBC Capital, Warner Bros, Golden Globes, Microsoft Locations: California, New, Friday's

☆ If You’re on Medicare, You Could Save Money on Drugs This Year
▼ + stars: | 2024-02-04 | by ( Mark Miller | ) www.nytimes.com time to read: +1 min

It’s the best news that few people seem to know about: Prescription drug costs are falling this year for more than a million seniors — in many cases, by thousands of dollars. Its changes to Medicare, which will help people who are enrolled in the prescription drug coverage plans known as Part D, are significant. expands eligibility for financial assistance with Part D costs for low-income seniors. The law has also authorized Medicare to negotiate prices for expensive drugs with pharmaceutical companies for the first time. The first negotiations will be over 10 drugs, including the blood thinners Eliquis and Xarelto and the diabetes drugs Jardiance and Januvia.

Persons: Biden, Jardiance Organizations: Medicare

☆ A Gen Z diabetic said a 3-month supply of insulin pumps would cost her $1,800 — even with insurance
▼ + stars: | 2024-02-03 | by ( Allie Kelly | ) www.businessinsider.com time to read: +7 min

However, others, like 25-year-old Cochrin, are still seeking some relief for the costs of insulin and other necessary diabetes tools, like insulin pumps and continuous glucose monitors. While the costs of insulin have skyrocketed, and the direct medical costs of treating diabetes have also increased by about 7% since 2017. AdvertisementEarlier this month, Cochrin posted a TikTok explaining that a 3-month supply of her insulin pumps would cost her $1,800, even after insurance. Her continuous glucose monitor doesn't cost her anything right now, but in the past, she paid $30 a month with insurance. AdvertisementDifferent people may have increased sensitivity to different types and brands of insulin, Cochrin said, but insurance companies sometimes only offer one option for coverage.

Persons: —, Grace Cochrin's, Joe Biden, Eli Lilly, Sanofi, it's, Cochrin, She's, Campbell Hutton Organizations: Service, American Diabetes Association, National Institutes of Health, Business, White, US Department of Health, Human Services, that's Locations: Charlotte, North Carolina

☆ Bristol Myers Squibb results top estimates as new drugs post strong sales growth
▼ + stars: | 2024-02-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. That group raked in $1.07 billion in sales for the quarter, up 66% from the $645 million for the year-earlier period. While its revenue outlook was in line with Wall Street estimates, it anticipates higher than expected earnings for the year. Analysts surveyed by LSEG expect full-year adjusted earnings of $7 per share and sales growth of 1.9%. Bristol Myers said Eliquis and Opdivo also contributed to the slight sales growth in the fourth quarter.

Persons: Bristol Myers, Revlimid, Eliquis, Opdivo, FactSet Organizations: Bristol Myers Squibb, LSEG, Bristol Myers, Wall, Bristol, Pfizer, Medicare

☆ Trump clemency recipient Philip Esformes reaches plea deal in Medicare fraud case
▼ + stars: | 2024-02-01 | by ( Dan Mangan | ) www.cnbc.com time to read: +2 min

Convicted Medicare fraudster Philip Esformes has reached a plea deal that could resolve a long-running, complicated criminal case that has included his 20-year prison sentence being commuted by former President Donald Trump in 2020, court filings show. Terms of Esformes' plea agreement with the Department of Justice were not included in the filings Thursday. A Miami federal judge scheduled Esformes' change of plea hearing and sentencing for Feb. 22. Esformes' lawyers have said they are unaware of any other case in which the DOJ retried a defendant whose criminal sentence in the same case was commuted by a president. Prosecutors at the time said it was "the largest single criminal health care fraud case ever brought against individuals" by the DOJ.

Persons: Philip Esformes, Harold, Donald Trump, Esformes, —, Denise Stemen, Stemen Organizations: Carole Pump Foundation, Hyatt, Department of Justice, Esformes, DOJ, Prosecutors Locations: Century City , California, Miami

☆ Here are Thursday's biggest analyst calls: Nvidia, Apple, Microsoft, Qualcomm, Target, AT&T, Tesla & more
▼ + stars: | 2024-02-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Thursday's biggest calls on Wall Street: Morgan Stanley downgrades ZoomInfo to equal weight from overweight Morgan Stanley said it sees a slowing recovery for the software company. Morgan Stanley reiterates General Motors as overweight Morgan Stanley said it's standing by the auto giant and that GM shares are "cheap." Mizuho reiterates Nvidia as buy Mizuho said it's standing by the stock heading into its GTC Conference in March. Morgan Stanley names Docebo a top pick Morgan Stanley named the ed-tech company a top pick. " Morgan Stanley reiterates Bloom Energy as overweight Morgan Stanley said the energy company is an "underappreciated AI winner."

Persons: Morgan Stanley downgrades ZoomInfo, Morgan Stanley, Oppenheimer, AAPL, it's, Mizuho, Goldman Sachs, Goldman, Redburn, Tesla, Daiwa, Jefferies, StoneCo, Wells, JPMorgan downgrades Lennox, LII, Docebo, Kraft Heinz, Mondelez, Kate McShane, Wolfe, Cash Organizations: OW, Apple, Motors, Nvidia, Conference, Citi, Qualcomm, Samsung, Deutsche Bank, Deutsche, Humana, Microsoft, Rockwell Automation, Rockwell, JPMorgan, UBS, SilverBow Resources, Regency, Kraft, Target, RBC downgrades New York Community Bancorp, RBC, New, Community Bancorp, Bloom Energy, Boston Scientific, Mizuho Locations: Boston

☆ US Government Sends Initial Offers for Medicare Drug Price Cuts
▼ + stars: | 2024-02-01 | by ( Feb. | At A.M. | ) www.usnews.com time to read: +1 min

(Reuters) - The Biden administration is sending drugmakers opening offers for the U.S. Medicare program's first ever price negotiations on Thursday, the White House said in a statement. President Joe Biden's signature Inflation Reduction Act (IRA) allows Medicare, which covers 66 million Americans mostly aged 65 and older, to negotiate prices for some of its most costly drugs. The initial offers have been sent to manufacturers of 10 high-cost medicines, which include Bristol Myers Squibb and Pfizer's blood thinner Eliquis, Merck & Co's diabetes drug Januvia and Johnson & Johnson's blood thinner Xarelto. The HHS and White House did not disclose details on the offers. (Reporting by Urvi Dugar and Sriparna Roy in Bengaluru; Editing by Toby Chopra and Sriraj Kalluvila)

Persons: Biden, Medicare program's, Joe Biden's, Januvia, Johnson, Urvi Dugar, Sriparna Roy, Toby Chopra, Sriraj Organizations: Reuters, U.S, Medicare, U.S . Department of Health, Human Services, Bristol Myers Squibb, Merck, HHS, White Locations: Bengaluru

☆ U.S. Makes Initial Offers in Medicare Drug Price Negotiations
▼ + stars: | 2024-02-01 | by ( Noah Weiland | More About Noah Weiland | ) www.nytimes.com time to read: +2 min

Why It Matters: The price offers kick off negotiations. The initial round of price offers is a key step in the negotiation process. The price negotiation program was created by the Inflation Reduction Act, the climate, tax and health care package that President Biden signed into law in 2022. Additional medications will be chosen for price negotiations in the coming years. A federal judge in Delaware heard arguments on Wednesday in a case brought by AstraZeneca, the maker of a diabetes drug that was selected for price negotiations.

Persons: ”, Andrew W, Mulcahy, Biden, Mr, drugmakers Organizations: Biden, RAND Corporation, Medicare, U.S . Chamber, Commerce, AstraZeneca Locations: Delaware

☆ 'He's a non-entity': House Democrats no longer see Dean Phillips as a threat — just a joke
▼ + stars: | 2024-02-01 | by ( Bryan Metzger | ) www.businessinsider.com time to read: +7 min

When Rep. Dean Phillips first began making noise about launching a quixotic presidential campaign, the mood among House Democrats might have best been described as anger and disbelief. Since launching his campaign, Phillips has generally been absent from Capitol Hill, effectively cutting down Democrats' ranks by one seat. AdvertisementOn Wednesday evening, Sen. Tina Smith made light of her Minnesota colleague's recent struggles in a video message to the Congressional Dinner, an annual gathering of reporters and lawmakers. At first, Phillips's campaign seemed to constitute a real threat to Biden, even if he was unlikely to actually defeat him. In a statement for this story, a Phillips spokesperson chastised his Democratic colleagues who now speak ill of him.

Persons: Dean Phillips, Sydney Kamlager, Dove, Axios, Phillips, Joe Biden, Sen, Tina Smith, Smith, Biden, Donald Trump, Maxwell Frost of Florida, — Phillips, Brendan Boyle, Alexandria Ocasio, Cortez, Dean's, Tom Williams, Angie Craig, Craig, wouldn't, Phillips's, we've, Dean, Jim Clyburn, Zach Gibson, Mark Pocan, Ro Khanna, Khanna, it's Organizations: Trump, Rep, Sydney, California congresswoman, Democratic, Capitol Hill, Biden, New, Democrats, Minnesota Democrat, Democratic Party, Twitter, South Carolina Democratic Party, California Locations: California, Minnesota, New Hampshire, Alexandria, New York, lockstep, South, Wisconsin

It is the first advertising company to reach a major settlement over the toll of opioids in the U.S. It faced a lawsuit in at least Massachusetts but settled with most states before they made court claims against it. James' office said the materials played up the abuse-deterrent properties of OxyContin and promoted increasing patients' doses. As part of the settlement, Publicis agreed to release internal documents detailing its work for Purdue and other companies that made opioids. The first began after OxyContin hit the market in 1996 and was linked mostly to prescription opioids, many of them generics.

Persons: Letitia James, Publicis, James, Bob Ferguson, Rosetta, ” Publicis, Sackler, OxyContin Organizations: Publicis, Publicis Groupe, New York, Purdue Pharma, Washington, Purdue, State Pharmacy, U.S, Supreme Locations: Paris, U.S, Massachusetts, Connecticut

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The company also is helping Japanese drugmaker Eisai sell another Alzheimer’s treatment, Leqembi, which already has full FDA approval. Leqembi is the first medicine that’s been convincingly shown to slow the cognitive decline caused by Alzheimer’s disease, though only modestly. Political Cartoons View All 253 ImagesAduhelm was the first new Alzheimer’s disease drug introduced in nearly two decades. But doctors were hesitant to prescribe the intravenous drug, given weak evidence that the drug slows Alzheimer’s.

Persons: drugmaker, Biogen, that’s, Aduhelm Organizations: Food and Drug Administration, Regulators, FDA, Cambridge, Inc Locations: Japanese, Cambridge , Massachusetts

☆ Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
▼ + stars: | 2024-01-31 | by ( Rebecca Robbins | More About Rebecca Robbins | ) www.nytimes.com time to read: +1 min

The drug maker Biogen said on Wednesday it would abandon its ownership rights to Aduhelm, an Alzheimer’s drug that had provoked fierce criticism of the company and regulators after it was approved based on weak evidence that it would help patients. The company will also stop a clinical trial that the Food and Drug Administration had ordered to confirm whether the drug is effective in slowing the progression of Alzheimer’s disease. Biogen’s decision closes out a yearslong saga that generated outrage and eroded trust in the regulatory process for bringing new medicines to market. adviser called the approval of the drug perhaps “the worst approval decision that the F.D.A. has made that I can remember.” A congressional inquiry later found that the F.D.A.’s process for approving Aduhelm was “rife with irregularities” and involved “lapses in protocol,” including unusually close collaboration with Biogen.

Persons: Biogen, Aduhelm Organizations: and Drug Administration

☆ Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
▼ + stars: | 2024-01-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer's drug Aduhelm to refocus the company's efforts to treat the memory-robbing disease. The biotech company will focus on rolling out Leqembi, a newly approved Alzheimer's drug it developed with Japanese drugmaker Eisai . The U.S. Food and Drug Administration greenlit Aduhelm in 2021 under a program that fast-tracks promising treatments. The company said it will redistribute a large portion of the resources associated with Aduhelm to the rest of its Alzheimer's drug portfolio. Among the other Alzheimer's drugs Biogen has in development is BIIB080, which targets a toxic protein called tau in the brain.

Persons: Biogen, Aduhelm Organizations: U.S . Food, Drug Administration, CNBC PRO Locations: U.S, Swiss

Part motel, part new-age clinic, the facility offers nightly rentals in rooms that come equipped with “BioHealers” –- canisters that the company claims exude “life force energy,” or biophotons. “There are some forces driving that: obviously the internet and social media, and distrust of traditional medicine, traditional science. Given the primary importance of health, it’s hardly surprising that unproven medical claims and products that seem too-good-to-be-true have a long history in America. “ Distrust of government and distrust of major institutions makes people vulnerable,” said Stephen Barrett, a psychiatrist and expert in unproven medical claims who launched the organization Quackwatch in the 1970s to highlight medical scams. As a result, low-level hucksters or those peddling unproven treatments often don’t get as much attention.

Persons: BUTLER, exude, Tesla, Dr, James Liu, ”, Liu, Timothy Caulfield, Medbeds, Donald Trump, “ I’m, medbeds, ” Liu, it’s, John Brinkley, they’ve, Alex Jones, Trump, Stephen Barrett, Elon Musk, Nikola Tesla, Seth Robinson, Robinson doesn’t, We’re, Tesla’s, I’ve, Caulfield, ” Caulfield, “ It’s, ” Tesla’s, Bahman Anvari, It’s Organizations: Tesla, MedBed, Penn State University, “, University of Alberta, Walmart, Associated Press, Drug Administration, Elon, FDA, AP, University of California Locations: Pa, Pittsburgh, China, New Jersey, Butler, Tennessee, America, Florida, Delaware, Riverside

Three names in the industry – Johnson & Johnson , Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. They join Bristol Myers Squibb CEO Chris Boerner, who agreed to the panel's initial invitation to appear. But why is the committee targeting Merck, J&J and Bristol Myers Squibb in the first place? J&J, Merck and Bristol Myers Squib are all suing to halt the talks, which will establish new prices that will go into effect in 2026. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer.

Persons: Annika Kim Constantino, – Johnson, Sen, Bernie Sanders, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Eli Lilly's, Januvia, Bristol Myers, He's, Biden, Merck's, Myers, Eliquis, Mike Perrone, it's Organizations: CNBC.com, Johnson, Merck, Bristol Myers Squibb, Bristol Myers, Medicare, Bristol, CNBC, pharma Locations: U.S, drugmakers

☆ 5 caregiving terms to help you access essential services and reduce expenses for an aging parent
▼ + stars: | 2024-01-30 | by ( Sharon Epperson | In Sharoneppersoncnbc | ) www.cnbc.com time to read: +5 min

The highest level of care is "skilled nursing care" for those who are chronically ill or disabled and can no longer care for themselves. Medicaid pays for most long-term care services — but only for people with low incomes and little savings. Long-term care insuranceDepending on the plan, long-term care insurance pays for services from at-home care to assisted living, memory care, skilled nursing care, and hospice. Long-term care insurance may have annual premiums that increase over time or may be included as a rider to a life insurance policy. Employers are increasingly offering long-term care insurance as a workplace benefit.

Persons: Abbe Udochi, AARP's Goyer, Ivory Johnson, Johnson, Couples, Goyer Organizations: Maskot, Getty, Healthcare Consulting, National Investment Center, Seniors Housing & Care, Medicare, Delancey Wealth Management, Washington , D.C, CNBC FA, American Association for, Care Insurance, Employers Locations: New York, Washington ,

“Here in Florida, you’ve had a real dose of Trumpism,” Biden told donors in nearby Jupiter, Florida where Trump owns a golf course. “You’re the reason Donald Trump is a defeated president,” Biden said to the attendees. Along with North Carolina, Florida is a state Biden lost in 2020 but which his campaign sees as a pickup opportunity. It’s a very tall order for the Biden campaign. The president lost Florida voters 65 and older to Trump by 10 points in 2020, a wider gap than his 5-point deficit nationally.

Persons: Biden, Donald Trump, Joe Biden’s, you’ve, ” Biden, ”, “, hadn’t, Trump’s, Republican megadonors, Nikki Haley, Biden’s, he’ll, Trump, MAGA, GOP Sen, Rick Scott, Ron DeSantis ’, Joe Biden, Joe Raedle, DeSantis, Donna Deegan, Nikki Fried, Fried, Tom Brenner, Democratic handwringing, That’s, Barack Obama, Bill Clinton Organizations: Trump, ” Air Force, Palm Beach International, Republican, Palm Beach, South, GOP, Republicans, Democrats, ., Sunshine State, Florida voters, Social Security, Medicare, Gov, University of Tampa, Democrat, Jacksonville, Florida Supreme, Florida Democrats, CNN, Democratic, Democratic Party, South Carolina's, State Fairgrounds, Reuters, ”, NBC News Locations: Jupiter, Miami , Florida Florida, Florida, Jupiter , Florida, New York, Palm, Palm Beach, South Carolina, Miami, North Carolina , Florida, Lago, Los Angeles, Columbia , South Carolina, Iowa

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
▼ + stars: | 2024-01-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Sen. Bernie Sanders, I-Vt., holds his news conference with Sen. Ed Markey, D-Mass., in the Capitol on Thursday, January 25, 2024, on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices. The CEOs of Merck and Johnson & Johnson have voluntarily agreed to testify at an upcoming Senate hearing on high drug prices in the U.S., Sen. Bernie Sanders announced Friday, as lawmakers ramp up efforts to rein in health-care costs for Americans. Meanwhile, Bristol Myers Squibb CEO Chris Boerner and another unnamed pharmaceutical CEO agreed to initial invitations to testify. The push to cut drug prices is one of the rare issues that has united both major political parties in recent years — though they have often backed different approaches to doing so. Last year, the Senate Health Committee similarly heard testimony from the CEOs of Moderna , Eli Lilly , Novo Nordisk and Sanofi on high drug prices.

Persons: Sen, Bernie Sanders, Ed Markey, Johnson, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Januvia, Bristol Myers, Joe Biden's, J, Eli Lilly Organizations: Merck, Johnson, Health, Education, Labor, Pensions, Bristol Myers, Bristol, J, Moderna, Novo Nordisk, Sanofi Locations: U.S

☆ Mammography AI can cost patients extra. Is it worth it?
▼ + stars: | 2024-01-26 | by ( Michelle Andrews | Kff Health News | ) edition.cnn.com time to read: +8 min

In recent years, AI software that helps radiologists detect problems or diagnose cancer using mammography has been moving into clinical use. This extra review has enormous potential to improve the detection of suspicious breast masses and lead to earlier diagnoses of breast cancer. With RadNet’s AI tool, “it’s as if all patients get the benefit of our very top performer.”But is the tech analysis worth the extra cost to patients? The health system has developed AI models and is testing the technology with mammograms but doesn’t yet offer it to patients, she said. In the late 1980s and early 1990s, “computer-assisted detection” software promised to improve breast cancer detection.

Persons: “, ”, Etta Pisano, RadNet, Gregory Sorensen, Sorensen, generalists, ” Sorensen, Laura Heacock, NYU Langone Health’s, Heacock, it’s, Constance Lehman, ” Lehman, RadNet’s, Dr, Sanjay Gupta, Christoph Lee, mammography, Robert Smith, ” Smith, Smith, we’re Organizations: Health, American College of Radiology, NYU, Cancer, “, National Cancer Institute, FDA, Medicare, Services, CMS, Radiology, Massachusetts General Hospital, Harvard Medical School, Imaging Research, Mass, Get CNN, CNN Health, Screening, Research, University of Washington School of Medicine, American Cancer Society, Kaiser Health, KFF Locations: Manhattan, Baltimore, RadNet, New York, New Jersey, mammograms, Boston, Massachusetts, United States, Europe, Sweden, U.S

Search resuls for: "Medicare"

25 mentions found